AI, Privacy, & Genomics: The Next Era of Drug Design


2020 has shed light on the unacknowledged void present in the drug manufacturing system despite the technological preferment and reduced period between the proposed drug and its availability on the shelf. On a whole, drug identification and discovery are becoming more difficult and have a higher rate of failure. Working with better data from the outset can improve this. That's where Artificial Intelligence comes in. Using genome sequencing, AI can process large amounts of data very quickly. This report studies recent developments in both Artificial Intelligence (AI) and drug R&D.

In addition to this, it discusses the crucial role AI will play and how its relation to available genetic data can shape how the industry works while keeping in check the importance of AI privacy and how multiparty access will deal with it.

To find out more about the privacy issues and solutions involved in AI and genomics, here is the link to the full report: 

How do you rate this article?



Akash Sinha
Akash Sinha

Akash has a background in digital marketing and works on UX and UI design. His passion is technological development, and he is currently exploring where emerging technologies will take society.

Connecting the Dots : Ferry
Connecting the Dots : Ferry

The dGen's Ambassador program has proven to be very successful, with new members joining from all over Europe and giving their invaluable insights for our research. Similarly, our newest Ambassador, Ferry Tillekens from Netherland, and I had the chance to speak, where he shared his insights on Dutch Tech's current state, the scope of expansion, and his work at 2Tokens, a Dutch not-for-profit foundation, and what makes dGen's approach unique.

Send a $0.01 microtip in crypto to the author, and earn yourself as you read!

20% to author / 80% to me.
We pay the tips from our rewards pool.